JP2024537098A5 - - Google Patents
Info
- Publication number
- JP2024537098A5 JP2024537098A5 JP2024520007A JP2024520007A JP2024537098A5 JP 2024537098 A5 JP2024537098 A5 JP 2024537098A5 JP 2024520007 A JP2024520007 A JP 2024520007A JP 2024520007 A JP2024520007 A JP 2024520007A JP 2024537098 A5 JP2024537098 A5 JP 2024537098A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ligand
- oligonucleotide compound
- composition according
- modified nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252596P | 2021-10-05 | 2021-10-05 | |
| US63/252,596 | 2021-10-05 | ||
| PCT/US2022/045664 WO2023059629A1 (en) | 2021-10-05 | 2022-10-04 | Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537098A JP2024537098A (ja) | 2024-10-10 |
| JP2024537098A5 true JP2024537098A5 (https=) | 2025-10-10 |
Family
ID=84332288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520007A Pending JP2024537098A (ja) | 2021-10-05 | 2022-10-04 | オリゴヌクレオチド化合物の遺伝子サイレンシング活性を増強するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250011779A1 (https=) |
| EP (1) | EP4413135A1 (https=) |
| JP (1) | JP2024537098A (https=) |
| CN (1) | CN118556125A (https=) |
| AU (1) | AU2022359289A1 (https=) |
| CA (1) | CA3234369A1 (https=) |
| MX (1) | MX2024004306A (https=) |
| WO (1) | WO2023059629A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202513799A (zh) * | 2023-06-02 | 2025-04-01 | 大陸商維亞臻生物技術（蘇州）有限公司 | 用於免疫類疾病的雙鏈核苷酸化合物及其用途 |
| WO2025231397A1 (en) * | 2024-05-03 | 2025-11-06 | Tenaya Therapeutics, Inc. | Modified hek cell lines for improved aav production |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5976567A (en) | 1995-06-07 | 1999-11-02 | Inex Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2487274A1 (en) | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| ES2702942T3 (es) | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| CA2685127C (en) | 2007-04-23 | 2019-01-08 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| EP3564374A1 (en) | 2013-06-21 | 2019-11-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
-
2022
- 2022-10-04 WO PCT/US2022/045664 patent/WO2023059629A1/en not_active Ceased
- 2022-10-04 CA CA3234369A patent/CA3234369A1/en active Pending
- 2022-10-04 JP JP2024520007A patent/JP2024537098A/ja active Pending
- 2022-10-04 AU AU2022359289A patent/AU2022359289A1/en active Pending
- 2022-10-04 EP EP22802312.3A patent/EP4413135A1/en active Pending
- 2022-10-04 CN CN202280078567.3A patent/CN118556125A/zh active Pending
- 2022-10-04 US US18/697,901 patent/US20250011779A1/en active Pending
- 2022-10-04 MX MX2024004306A patent/MX2024004306A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023504744A5 (https=) | ||
| JP2023103244A5 (https=) | ||
| JP2023537943A5 (https=) | ||
| JP2024537098A5 (https=) | ||
| JP2021006029A5 (https=) | ||
| AU2013299332B2 (en) | EpCAM aptamer for detection of cancer stem cells | |
| JP2022511866A5 (https=) | ||
| JP2011511636A5 (https=) | ||
| JP2021511042A5 (https=) | ||
| TW202227626A (zh) | Ｄｕｘ４抑制劑及其使用方法 | |
| JP2023538284A5 (https=) | ||
| JP2024505151A5 (https=) | ||
| Dai et al. | Pancreatic cancer: Nucleic acid drug discovery and targeted therapy | |
| Sarli et al. | Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo | |
| CN109718241A (zh) | 一种肿瘤的基于核酸的靶向治疗方法 | |
| JP2021520355A (ja) | Ｔｍ上昇ヌクレオチドで修飾された二本鎖核酸阻害剤分子 | |
| JP2024538859A5 (https=) | ||
| TW202400193A (zh) | 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法 | |
| Le et al. | Evaluation of DNA segments in 2′-modified RNA sequences in designing efficient splice switching antisense oligonucleotides | |
| JP2024528701A5 (https=) | ||
| JPWO2019044974A1 (ja) | スモールガイドアンチセンス核酸とその使用 | |
| JP2021536236A (ja) | 小型化ヘアピンＲＮＡｉトリガー（ｍｘＲＮＡ）及びそれらの使用方法 | |
| Rayburn et al. | Antisense-based cancer therapeutics: are we there yet? | |
| TW202530408A (zh) | 用於治療非酒精性脂肪肝病的組合物與方法 | |
| WO2024228030A2 (en) | Dual silencing |